CRISPR

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade CRISPR 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CRSP

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. 

CEO
Samarth Kulkarni
CEOSamarth Kulkarni
Employees
Employees
Headquarters
Zug, Zug
HeadquartersZug, Zug
Founded
2013
Founded2013
Employees
Employees

CRSP Key Statistics

Market cap
5.39B
Market cap5.39B
Price-Earnings ratio
-11.72
Price-Earnings ratio-11.72
Dividend yield
Dividend yield
Average volume
1.23M
Average volume1.23M
High today
High today
Low today
Low today
Open price
$56.06
Open price$56.06
Volume
651.00
Volume651.00
52 Week high
$78.48
52 Week high$78.48
52 Week low
$44.12
52 Week low$44.12

Stock Snapshot

With a market cap of 5.39B, CRISPR(CRSP) trades at $55.85. The stock has a price-to-earnings ratio of -11.72.

CRISPR(CRSP) stock opened on 2026-09-08 at $56.06. The price climbed to — and dipped to —.

CRISPR(CRSP) shares are trading with a volume of 651, against a daily average of 1.23M.

During the past year, CRISPR(CRSP) stock moved between $44.12 at its lowest and $78.48 at its peak.

During the past year, CRISPR(CRSP) stock moved between $44.12 at its lowest and $78.48 at its peak.

CRSP News

TipRanks 20h
Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321 - TipRanks

...

Citi says Novartis news increases likelihood Crispr prioritizes next-gen CTX321 - TipRanks
TipRanks 21h
Crispr Therapeutics Maintained at Buy as Lp(a) Program Prospects Support Unchanged $88 Price Target

Analyst Yigal Nochomovitz of Citi maintained a Buy rating on Crispr Therapeutics AG, retaining the price target of $88.00. Yigal Nochomovitz has given his Buy...

Analyst ratings

57%

of 23 ratings
Buy
56.5%
Hold
43.5%
Sell
0%

People also own

Based on the portfolios of people who own CRSP. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.